Cargando…
Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609954/ https://www.ncbi.nlm.nih.gov/pubmed/28969022 http://dx.doi.org/10.18632/oncotarget.19476 |
_version_ | 1783265697144504320 |
---|---|
author | Du, Meijun Giridhar, Karthik V. Tian, Yijun Tschannen, Michael R. Zhu, Jing Huang, Chiang-Ching Kilari, Deepak Kohli, Manish Wang, Liang |
author_facet | Du, Meijun Giridhar, Karthik V. Tian, Yijun Tschannen, Michael R. Zhu, Jing Huang, Chiang-Ching Kilari, Deepak Kohli, Manish Wang, Liang |
author_sort | Du, Meijun |
collection | PubMed |
description | Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays. Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54). A multivariate analysis of miR-let-7i-5p with the clinical factor-based Memorial Sloan-Kettering Cancer Center (MSKCC) score improved survival prediction from an area under the curve (AUC) of 0.58 for MSKCC score to an average AUC of 0.64 across 48-month follow-up time. The multivariate model was able to define a high-risk group with median survival of 14 months and low risk group of 39 months (P=0.0002, HR=3.43, 95%CI, 2.73-24.15). Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC. |
format | Online Article Text |
id | pubmed-5609954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56099542017-09-29 Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer Du, Meijun Giridhar, Karthik V. Tian, Yijun Tschannen, Michael R. Zhu, Jing Huang, Chiang-Ching Kilari, Deepak Kohli, Manish Wang, Liang Oncotarget Research Paper Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays. Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54). A multivariate analysis of miR-let-7i-5p with the clinical factor-based Memorial Sloan-Kettering Cancer Center (MSKCC) score improved survival prediction from an area under the curve (AUC) of 0.58 for MSKCC score to an average AUC of 0.64 across 48-month follow-up time. The multivariate model was able to define a high-risk group with median survival of 14 months and low risk group of 39 months (P=0.0002, HR=3.43, 95%CI, 2.73-24.15). Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC. Impact Journals LLC 2017-07-22 /pmc/articles/PMC5609954/ /pubmed/28969022 http://dx.doi.org/10.18632/oncotarget.19476 Text en Copyright: © 2017 Du et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Du, Meijun Giridhar, Karthik V. Tian, Yijun Tschannen, Michael R. Zhu, Jing Huang, Chiang-Ching Kilari, Deepak Kohli, Manish Wang, Liang Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer |
title | Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer |
title_full | Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer |
title_fullStr | Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer |
title_full_unstemmed | Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer |
title_short | Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer |
title_sort | plasma exosomal mirnas-based prognosis in metastatic kidney cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609954/ https://www.ncbi.nlm.nih.gov/pubmed/28969022 http://dx.doi.org/10.18632/oncotarget.19476 |
work_keys_str_mv | AT dumeijun plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT giridharkarthikv plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT tianyijun plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT tschannenmichaelr plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT zhujing plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT huangchiangching plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT kilarideepak plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT kohlimanish plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer AT wangliang plasmaexosomalmirnasbasedprognosisinmetastatickidneycancer |